ABOUT
A cell-by-cell reading of the BPC-157 TB-500 record
Two peptide literatures and one regulatory record, laid out cell by cell. The word 'telehealth' here names a reading position, not a service — no clinic, no consults, no vendor.
What this site is
Wolverine Telehealth reads and lays out the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide blend pairing BPC-157 with the Thymosin Beta-4 fragment TB-500 — panel by panel. Despite the name, no exam room stands behind it: there are no clinicians here, no diagnosis, and no medical advice. It makes and moves no product; nothing is manufactured, sold, or shipped from this address. What it lays down is a reading of published science and of the public regulatory record, each panel cited.
The site is organized as a bento board on purpose. The Wolverine blend is two distinct peptides, each with its own mechanism and its own literature, joined by a synergy that has never been tested. A mosaic of cells is the honest way to show that: each constituent gets its own panel, the shared repair rationale gets its own, and the gaps — no controlled combination study, no validated blend dose, both components in FDA 503A Category 2 — get their own deliberate cells rather than being smoothed over.
On the word 'telehealth' in our name
The 'telehealth' in this domain is editorial framing — where this reader sits relative to the medicinal-access conversation around peptides — and not a description of anything on offer. No telehealth consultation runs here, no reader is connected to a prescriber, and access to no substance is arranged. The regulatory landscape is described in general terms, with the FDA record cited directly.
When we describe the lawful compounded-access pathway on the Wolverine legal status and FDA 503A category page, we do so as general information about the framework, naming no pharmacy, clinic, telehealth provider, or vendor. That page exists because readers ask whether the blend is legal and how access works; answering accurately is editorial service, not medical or legal advice.
How we handle evidence
Every quantitative claim on this site is attributed to a specific study, listed in the full reference list. Where a finding belongs to one component, we say so; where it was generated with full-length Thymosin Beta-4 rather than the TB-500 heptapeptide, we flag the distinction. Where the blend itself has no data — which is most places a person would expect data — we say that plainly rather than borrowing a component result to fill the gap.
We describe doses as they were administered in animal studies, never as human instructions. We do not recommend protocols. The aim is a board a careful reader can verify line by line against the sources, and a record that stays honest about what two separately studied peptides do and do not jointly demonstrate.